Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: review decision information

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: appendix A - RPP decision paper - June 2015 (PDF 66 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: review decision - May 2015 information

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: appendix A - matrix of stakeholders (PDF 100 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: appendix B - GE proposal paper April 2015 (PDF 380 KB)

TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: press release information

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: equality impact assessment - TA Guidance in development (PDF 75 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: final appraisal determination information

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: final appraisal determination guidance (PDF 256 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 216 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Consultee and commentator comments on the ACD

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: AntiCoagulation Europe (PDF 42 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Bayer (PDF 333 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Commissioning Support Appraisal Service (PDF 358 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Department of Health (PDF 6.8 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Leo Pharma (PDF 131 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: NHS North of Tyneside (PDF 6.8 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Pfizer (PDF 68 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Royal College of Nursing (PDF 65 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: Royal College of Physicians endorse the response by Royal College of Pathologists and British Society for Haematology (PDF 125 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: The Vascular society (PDF 118 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: ERG's response to Bayer's comment on the ACD (PDF 463 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: comments on the ACD from the public through the NICE website (PDF 37 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: appraisal consultation

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: appraisal consultation document information

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: evaluation report

Pre-meeting briefing (PDF 385 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: evidence review group report

Evidence Review Group report (PDF 2.23 MB)

Evidence review group report replacement pages (PDF 1.06 MB)

Bayer (PDF 3.18 MB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: patient group, professional group and NHS organisation submission statements

AntiCoagulation Europe (PDF 103 KB)

Lifeblood: The Thrombosis Charity (PDF 76 KB)

Northumberland Care Trust (PDF 73 KB)

Royal College of Nursing (PDF 47 KB)

Royal College of Pathologists & British Society of Haematology (PDF 183 KB)

United Kingdom Clinical Pharmacy Association (UKCPA) (PDF 121 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: expert written personal statements

Arya (PDF 93 KB)

Bevan (PDF 26 KB)

Eaton (PDF 31 KB)

Stephens-Boal (PDF 25 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: final scope (PDF 24 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: final matrix (PDF 58 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: response to consultee and commentator comments on the draft scope (PDF 247 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: equality impact assessment - scoping (PDF 44 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: draft scope (PDF 51 KB)

Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: provisional matrix (PDF 58 KB)